Eagle Pharmaceuticals (NASDAQ:EGRX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research note issued to investors on Friday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Price Performance

NASDAQ:EGRX opened at $1.94 on Friday. The firm’s fifty day simple moving average is $1.58 and its 200-day simple moving average is $1.07. Eagle Pharmaceuticals has a fifty-two week low of $1.50 and a fifty-two week high of $2.00.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.